Hypofibrinolysis is a risk factor for arterial thrombosis at young age

British Journal of Haematology

Volumn 145, Issue 1, 2009, Pages 115-120

  Guimarães, Ana H C ^a   De Bruijne, Emile L E ^a,b   Lisman, Ton ^c   Dippel, Diederik W J ^a   Deckers, Jaap W ^a   Poldermans, Don ^a   Rijken, Dingeman C ^a   Leebeek, Frank W G ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b RED CROSS HOSPITAL   (Netherlands)

^c UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Arterial thrombosis; Fibrinolysis; Ischaemic stroke; Myocardial infarction

Indexed keywords

FIBRINOLYTIC FACTOR;

ADULT; ARTERY DISEASE; ARTERY THROMBOSIS; ARTICLE; BLOOD CLOT LYSIS; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; CORONARY ARTERY DISEASE; FEMALE; FIBRINOLYSIS; GROUPS BY AGE; HUMAN; HYPOFIBRINOLYSIS; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; POPULATION BASED CASE CONTROL STUDY; PRIORITY JOURNAL; RISK FACTOR; SURVIVOR;

EID: 61849085308     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2008.07568.x     Document Type: Article

References (22)

1. Alessi, M.C. Juhan-Vague, I. (2006) PAI-1 and the metabolic syndrome: links, causes, and consequences. Arteriosclerosis, Thrombosis, and Vascular Biology, 26, 2200 2207.
2. Booth, N.A. (1999) Fibrinolysis and thrombosis. Baillieres Best Practice Research Clinical Haematology, 12, 423 433.
3. Catena, C., Novello, M., Lapenna, R., Baroselli, S., Colussi, G., Nadalini, E., Favret, G., Cavarape, A., Soardo, G. Sechi, L.A. (2005) New risk factors for atherosclerosis in hypertension: focus on the prothrombotic state and lipoprotein(a). Journal of Hypertension, 23, 1617 1631.
4. Dormandy, J.A. Rutherford, R.B. (2000) Management of peripheral arterial disease (PAD). TASC Working Group. TransAtlantic Inter-Society Consensus (TASC). Journal of Vascular Surgery, 31, S1 S296.
5. Feinbloom, D. Bauer, K.A. (2005) Assessment of hemostatic risk factors in predicting arterial thrombotic events. Arteriosclerosis, Thrombosis, and Vascular Biology, 25, 2043 2053.
6. Ladenvall, C., Gils, A., Jood, K., Blomstrand, C., Declerck, P.J. Jern, C. (2007) Thrombin activatable fibrinolysis inhibitor activation peptide shows association with all major subtypes of ischemic stroke and with TAFI gene variation. Arteriosclerosis, Thrombosis, and Vascular Biology, 27, 955 962.
7. Leebeek, F.W., Goor, M.P., Guimaraes, A.H., Brouwers, G.J., Maat, M.P., Dippel, D.W. Rijken, D.C. (2005) High functional levels of thrombin-activatable fibrinolysis inhibitor are associated with an increased risk of first ischemic stroke. Journal of Thrombosis Haemostasis, 3, 2211 2218.
8. Lijfering, W.M., Veeger, N.J., Brouwer, J.L. van der Meer, J. (2007) The risk of venous and arterial thrombosis in hyperhomocysteinemic subjects may be a result of elevated factor VIII levels. Haematologica, 92, 1703 1706.
9. Lisman, T., Leebeek, F.W., Mosnier, L.O., Bouma, B.N., Meijers, J.C., Janssen, H.L., Nieuwenhuis, H.K. De Groot, P.G. (2001) Thrombin-activatable fibrinolysis inhibitor deficiency in cirrhosis is not associated with increased plasma fibrinolysis. Gastroenterology, 121, 131 139.
10. Lisman, T., de Groot, P.G., Meijers, J.C. Rosendaal, F.R. (2005) Reduced plasma fibrinolytic potential is a risk factor for venous thrombosis. Blood, 105, 1102 1105.
11. MacCallum, P.K. Meade, T.W. (1999) Haemostatic function, arterial disease and the prevention of arterial thrombosis. Baillieres Best Practice Research Clinical Haematology, 12, 577 599.
12. Meade, T.W., Ruddock, V., Stirling, Y., Chakrabarti, R. Miller, G.J. (1993) Fibrinolytic activity, clotting factors, and long-term incidence of ischaemic heart disease in the Northwick Park Heart Study. Lancet, 342, 1076 1079.
13. Meltzer, M.E., Doggen, C.J., de Groot, P.G., Rosendaal, F.R. Lisman, T. (2007) Fibrinolysis and the risk of venous and arterial thrombosis. Current Opinion in Hematology, 14, 242 248.
14. Munkvad, S., Gram, J. Jespersen, J. (1990) A depression of active tissue plasminogen activator in plasma characterizes patients with unstable angina pectoris who develop myocardial infarction. European Heart Journal, 11, 525 528.
15. Pasternak, R.C., Grundy, S.M., Levy, D. Thompson, P.D. (1996) 27th Bethesda Conference: matching the intensity of risk factor management with the hazard for coronary disease events. Task Force 3. Spectrum of risk factors for coronary heart disease. Journal of the American College of Cardiology, 27, 978 990.
16. Prins, M.H. Hirsh, J. (1991) A critical review of the relationship between impaired fibrinolysis and myocardial infarction. American Heart Journal, 122, 545 551.
17. Rosendaal, F.R. (1999) Venous thrombosis: a multicausal disease. Lancet, 353, 1167 1173.
18. Smith, A., Patterson, C., Yarnell, J., Rumley, A., Ben-Shlomo, Y. Lowe, G. (2005) Which hemostatic markers add to the predictive value of conventional risk factors for coronary heart disease and ischemic stroke? The Caerphilly Study. Circulation, 112, 3080 3087.
19. The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (2001) Executive summary of the Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Journal of the American Medical Association, 285, 2486 2497.
20. Wilhelmsen, L., Svardsudd, K., Korsan-Bengtsen, K., Larsson, B., Welin, L. Tibblin, G. (1984) Fibrinogen as a risk factor for stroke and myocardial infarction. New England Journal of Medicine, 311, 501 505.
21. Ye, Z., Liu, E.H., Higgins, J.P., Keavney, B.D., Lowe, G.D., Collins, R. Danesh, J. (2006) Seven haemostatic gene polymorphisms in coronary disease: meta-analysis of 66,155 cases and 91,307 controls. Lancet, 367, 651 658.
22. Zorio, E., Castello, R., Falco, C., Espana, F., Osa, A., Almenar, L., Aznar, J. Estelles, A. (2003) Thrombin-activatable fibrinolysis inhibitor in young patients with myocardial infarction and its relationship with the fibrinolytic function and the protein C system. British Journal of Haematology, 122, 958 965.